arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GENELUX Corp

GNLX
$2.51 ▼ -0.09 (-3.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

GENELUX Corp faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $112.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -47.3%
FCF / Share $-0.18
Trailing P/E
Price / Book 7.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-8.93M
↓ -19.2%
FCF / Share Free cash flow per share
$-0.18
↓ -12.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters